INNOVIVA, INC. Marketable Securities (Current)
INNOVIVA, INC. (INVA) had Marketable Securities (Current) of $282.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2022-11-09
- 2022-09-30: Marketable Securities, Current $282.00K.
- 2021-12-31: Marketable Securities, Current $0.00.
- 2012-03-31: Marketable Securities, Current $185.85M.
- 2011-12-31: Marketable Securities, Current $196.14M.
| Period end | Marketable Securities, Current |
|---|---|
| 2022-09-30 | $282.00K 10-Q · filed 2022-11-09 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-09 |
| 2012-03-31 | $185.85M 10-Q · filed 2012-05-02 |
| 2011-12-31 | $196.14M 10-Q · filed 2012-05-02 |
| 2011-09-30 | $202.43M 10-Q · filed 2011-11-02 |
| 2011-06-30 | $193.23M 10-Q · filed 2011-08-03 |
| 2010-12-31 | $146.30M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |